CSBR
$10.68
Champions Oncolog
($.22)
(2.02%)
CSBR
Earnings Whisper ®
N/A
2nd Quarter October 2020
Consensus:  $0.00
Revenue:  $9.63 Mil
Monday
Dec 14
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when CSBR reports earnings?
Beat
Meet
Miss

Where is CSBR's stock price going from here?
Up
Flat
Down
Stock chart of CSBR
Analysts
Summary of analysts' recommendations for CSBR
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents. Champions Oncology, Inc. is based in Baltimore, Maryland.